-
1
-
-
0028057250
-
Depletion on B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
-
Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion on B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
-
(1994)
Blood
, vol.83
, pp. 435-445
-
-
Reff, M.E.1
Carner, K.2
Chambers, K.S.3
Chinn, P.C.4
Leonard, J.E.5
Raab, R.6
-
2
-
-
0345337254
-
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
-
McLaughlin P., Grillo-Lopez A., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
-
(1998)
J Clin Oncol
, vol.16
, pp. 2825-2833
-
-
McLaughlin, P.1
Grillo-Lopez, A.2
Link, B.K.3
Levy, R.4
Czuczman, M.S.5
Williams, M.E.6
-
3
-
-
0036993543
-
Effective B cell depletion with rituximab in the treatment of autoimmune diseases
-
Kneitz C., Wilhelm M., and Tony H.P. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunology 206 (2002) 519-527
-
(2002)
Immunology
, vol.206
, pp. 519-527
-
-
Kneitz, C.1
Wilhelm, M.2
Tony, H.P.3
-
4
-
-
37249092920
-
The potential utility of B cell-targeted biologic therapy in autoimmune diseases
-
Arkfield D.G. The potential utility of B cell-targeted biologic therapy in autoimmune diseases. Rheumatol Int 28 (2008) 205-215
-
(2008)
Rheumatol Int
, vol.28
, pp. 205-215
-
-
Arkfield, D.G.1
-
5
-
-
58149464696
-
A review of the current use of rituximab in autoimmune diseases
-
Gürcan H.M., Keskin D.B., Stern J.N., Nitzberg M.A., Shekani H., and Ahmed A.R. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9 (2008) 10-25
-
(2008)
Int Immunopharmacol
, vol.9
, pp. 10-25
-
-
Gürcan, H.M.1
Keskin, D.B.2
Stern, J.N.3
Nitzberg, M.A.4
Shekani, H.5
Ahmed, A.R.6
-
7
-
-
0035883071
-
Rituxiamb chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
-
Stasi R., Pagano A., Stipa E., and Amadori S. Rituxiamb chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 (2001) 952-957
-
(2001)
Blood
, vol.98
, pp. 952-957
-
-
Stasi, R.1
Pagano, A.2
Stipa, E.3
Amadori, S.4
-
8
-
-
40949159424
-
Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis
-
Garcia-Chavez J., Majluf-Cruz A., Montiel-Cervantes L., Esparza M.G.-R., and Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 86 (2007) 871-877
-
(2007)
Ann Hematol
, vol.86
, pp. 871-877
-
-
Garcia-Chavez, J.1
Majluf-Cruz, A.2
Montiel-Cervantes, L.3
Esparza, M.G.-R.4
Vela-Ojeda, J.5
-
9
-
-
49349113937
-
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long term follow-up results
-
Medeot M., Zaja F., Vianelli N., Battista M., Baccarani M., Patriarca F., et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long term follow-up results. Eur J Haematol 81 (2008) 165-169
-
(2008)
Eur J Haematol
, vol.81
, pp. 165-169
-
-
Medeot, M.1
Zaja, F.2
Vianelli, N.3
Battista, M.4
Baccarani, M.5
Patriarca, F.6
-
10
-
-
0034092297
-
Approaches for identifying and defining environmentally associated rheumatic disorders
-
Miller F.W., Hess E.V., Clauw D.J., Hertzman P.A., Pincus T., Silver R.M., et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheumatol 43 (2000) 243-249
-
(2000)
Arthritis Rheumatol
, vol.43
, pp. 243-249
-
-
Miller, F.W.1
Hess, E.V.2
Clauw, D.J.3
Hertzman, P.A.4
Pincus, T.5
Silver, R.M.6
-
11
-
-
54349123783
-
B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders
-
Stübgen J.P. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. J Neuroimmunol 204 (2008) 1-12
-
(2008)
J Neuroimmunol
, vol.204
, pp. 1-12
-
-
Stübgen, J.P.1
-
12
-
-
23244441588
-
Multiple sclerosis following splenectomy as treatment for idiopathic thrombocytopenic purpura
-
Matsui H., Udaka F., Tamura A., Oda M., Kubori T., Nishinaka K., et al. Multiple sclerosis following splenectomy as treatment for idiopathic thrombocytopenic purpura. Intern Med 44 (2005) 747-749
-
(2005)
Intern Med
, vol.44
, pp. 747-749
-
-
Matsui, H.1
Udaka, F.2
Tamura, A.3
Oda, M.4
Kubori, T.5
Nishinaka, K.6
-
13
-
-
33745334334
-
Revised diagnostic criteria for neuromyelitis optica
-
Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., and Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 66 (2006) 1485-1489
-
(2006)
Neurology
, vol.66
, pp. 1485-1489
-
-
Wingerchuk, D.M.1
Lennon, V.A.2
Pittock, S.J.3
Lucchinetti, C.F.4
Weinshenker, B.G.5
-
14
-
-
33745360142
-
The lumping and splitting of inflammatory CNS disease
-
Kerr D.A. The lumping and splitting of inflammatory CNS disease. Neurology 66 (2006) 1466-1467
-
(2006)
Neurology
, vol.66
, pp. 1466-1467
-
-
Kerr, D.A.1
-
15
-
-
34248354831
-
Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis
-
Wingerchuk D.M., and Lucchinetti C.F. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 20 (2007) 343-350
-
(2007)
Curr Opin Neurol
, vol.20
, pp. 343-350
-
-
Wingerchuk, D.M.1
Lucchinetti, C.F.2
-
16
-
-
59349104779
-
Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders
-
Petereit H., and Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler 15 (2009) 189-192
-
(2009)
Mult Scler
, vol.15
, pp. 189-192
-
-
Petereit, H.1
Rubbert-Roth, A.2
-
17
-
-
33846578563
-
The immunology of inflammatory demyelinating disease
-
Compston A. (Ed), Churchill Livingston, London
-
Wekerle H., and Lassmann H. The immunology of inflammatory demyelinating disease. In: Compston A. (Ed). McAlpine's multiple sclerosis (2006), Churchill Livingston, London 491-555
-
(2006)
McAlpine's multiple sclerosis
, pp. 491-555
-
-
Wekerle, H.1
Lassmann, H.2
-
18
-
-
33751085414
-
Rituximab reduces B cells and T cells in the cerebrospinal fluid of multiple sclerosis patients
-
Cross A.H., Stark J.L., Lauber J., Ramsbottom M.J., and Lyons J.-A. Rituximab reduces B cells and T cells in the cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180 (2006) 63-70
-
(2006)
J Neuroimmunol
, vol.180
, pp. 63-70
-
-
Cross, A.H.1
Stark, J.L.2
Lauber, J.3
Ramsbottom, M.J.4
Lyons, J.-A.5
-
19
-
-
45249085670
-
Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells
-
Liossis S.N., and Sfikakis P.P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 127 (2008) 280-285
-
(2008)
Clin Immunol
, vol.127
, pp. 280-285
-
-
Liossis, S.N.1
Sfikakis, P.P.2
-
20
-
-
0033214207
-
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
-
Winkler U., Jensen M., Manzke O., Schultz H., Diehl V., and Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94 (1999) 2217-2224
-
(1999)
Blood
, vol.94
, pp. 2217-2224
-
-
Winkler, U.1
Jensen, M.2
Manzke, O.3
Schultz, H.4
Diehl, V.5
Engert, A.6
-
21
-
-
0026493624
-
Synergy between encephalitogenic T cells and myelin basic protein-specific antibodies in the induction of experimental autoimmune encephalomyelitis
-
Myers K.J., Sprent J., Dougherty J.P., and Ron Y. Synergy between encephalitogenic T cells and myelin basic protein-specific antibodies in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 41 (1992) 1-8
-
(1992)
J Neuroimmunol
, vol.41
, pp. 1-8
-
-
Myers, K.J.1
Sprent, J.2
Dougherty, J.P.3
Ron, Y.4
-
22
-
-
33750627447
-
Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment
-
Antel J., and Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol 180 (2008) 3-8
-
(2008)
J Neuroimmunol
, vol.180
, pp. 3-8
-
-
Antel, J.1
Bar-Or, A.2
-
23
-
-
41649112738
-
The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies
-
Supplement
-
Racke M. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol 21 (2008) S9-S18 Supplement
-
(2008)
Curr Opin Neurol
, vol.21
-
-
Racke, M.1
|